Alumis Inc. ALMS 深 滬
等待開盤 09-25 09:30:00 美东时间
4.14
+0.040
+0.98%
華盛通- 最 高4.29
- 今 開4.11
- 成交量 40.18万股
- 最 低 4.07
- 昨 收 4.10
- 總市值 2.25亿
- 52周最高 13.11
- 市盈率 靜 --
- 換手率 0.74%
- 52周最低 2.7601
- 委 比 -1.52%
- 總股本 5440.55万
- 歷史最高 13.53
- 量 比 0.55
- 振 幅 5.37%
- 歷史最低 2.7601
- 每 手 1
- 風險率 2.78%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Alumis Inc. Updates Corporate Presentation on Pipeline
Alumis Inc. ( ($ALMS) ) has shared an update. On September 3, 2025, Alumis Inc....
09-03 18:28
Alumis to Participate in Upcoming September Investor Conferences
Alumis Inc., a late-stage biopharma company, announced its participation in six investor conferences in September 2025 to discuss its targeted therapies for immune-mediated diseases. Company updates will be shared at events including the Cantor Global Healthcare Conference, Wells Fargo Healthcare Conference, Morgan Stanley Global Healthcare Conference, H.C. Wainwright Global Investment Conference, Baird Global Healthcare Conference, and Stifel Im...
08-29 11:00
Alumis Q2 Sales $2.67M Beat $2.00M Estimate
Alumis (NASDAQ:ALMS) reported quarterly sales of $2.67 million which beat the analyst consensus estimate of $2.00 million by 33.30 percent.
08-14 04:28
Alumis Inc. Concludes 2025 Annual Stockholders Meeting
The latest announcement is out from Alumis Inc. ( ($ALMS) ). On July 30, 2025, ...
08-05 04:41
Wall Street Analysts Are Bullish on Top Materials Picks
There’s a lot to be optimistic about in the Materials sector as 2 analysts just...
07-28 13:10
Alumis Completes Patient Enrollment In Global LUMUS Phase 2b Trial Of ESK-001, Next-Gen Oral Tyrosine Kinase 2 Inhibitor, For Treatment Of SLE; Topline Readout Expected In Q3 2026
Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the completion of patient enrollment in its global
07-24 19:35
Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus
Alumis Inc. announced the completion of patient enrollment in its global LUMUS Phase 2b trial for ESK-001, a next-generation oral TYK2 inhibitor, targeting systemic lupus erythematosus (SLE). The trial enrolled 408 patients and aims to assess disease activity improvements using the BICLA endpoint at Week 48. Topline data is expected in Q3 2026. ESK-001, designed to selectively target inflammatory drivers, has shown promising results in earlier st...
07-24 11:30
Alumis files $400M mixed securities shelf
Alumis (NASDAQ:ALMS) filed $400M mixed securities shelf. Filing More on Alumis Acelyrin gains as Trium Capital rebuffs M&A deal with Alumis Alumis, ACELYRIN amend proposed merger pact
07-04 02:57
美股大行评级 | 潜在涨幅434.95%！VNRX获Jones Trading首予"买入"评级，目标价3美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139478829918380033.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Metsera(MTSR)"买入"评级，目标价从56美元升至62美元</p> <p>• 摩根大通：维持Avidity Biosciences(RNA)"超配"评级，目标价从57美元升至59美元</
06-11 09:43
